Use of physiologically‐based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity
Authors:
- Jacqueline G. GerhartJGJacqueline G. Gerhart
- Fernando O. CarreñoFCFernando O. Carreño
- Jennifer L. FordJFJennifer L. Ford
- Andrea N. EdgintonAEAndrea N. Edginton
- Eliana M. PerrinEPEliana M. Perrin
- Kevin M. WattKWKevin M. Watt
- Andrew M. AtzAAAndrew M. Atz
- Daniel GonzalezDGDaniel Gonzalez
- Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering CommitteeBCBest Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee
Open Access
- 2 May 2022
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (6) , 778-791
Abstract
Obesity is an increasingly alarming public health threat, with nearly 20% of children classified as obese in the United States today. Children with obesity are commonly prescribed the opioids fentanyl and methadone, and accurate dosing is critical to reducing the risk of serious adverse events associated with overexposure. However, pharmacokinetic studies in children with obesity are challenging to conduct, so there is limited information to guide fentanyl and methadone dosing in these children. To address this clinical knowledge gap, physiologically‐based pharmacokinetic models of fentanyl and methadone were developed in adults and scaled to children with and without obesity to explore the interplay of obesity, age, and pharmacogenomics. These models included key obesity‐induced changes in physiology and pharmacogenomic effects. Model predictions captured observed concentrations in children with obesity well, with an overall average fold error of 0.72 and 1.08 for fentanyl and methadone, respectively. Model simulations support a reduced fentanyl dose (1 vs. 2 μg/kg/h) starting at an earlier age (6 years) in virtual children with obesity, highlighting the importance of considering both age and obesity status when selecting an infusion rate most likely to achieve steady‐state concentrations within the target range. Methadone dosing simulations highlight the importance of considering genotype in addition to obesity status when possible, as cytochrome P450 (CYP)2B6*6/*6 virtual children with obesity required half the dose to match the exposure of wildtype children without obesity. This physiologically‐based pharmacokinetic modeling approach can be applied to explore dosing of other critical drugs in children with obesity.Keywords
Funding Information
- National Institutes of Health
- American Foundation for Pharmaceutical Education
- National Institute of General Medical Sciences (T32GM122741)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (1R01HD102949‐01A1, 5R01HD096435‐04, HHSN275201000003I, 5R01HD096435)
This publication has 45 references indexed in Scilit:
- Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceFrontiers in Genetics, 2013
- Clinical Tracking of Severely Obese Children: A New Growth ChartPediatrics, 2012
- Perioperative Pharmacokinetics of Methadone in AdolescentsAnesthesiology, 2011
- Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese PatientsClinical Pharmacokinetics, 2011
- Methadone Pharmacokinetics Are Independent of Cytochrome P4503A (CYP3A) Activity and Gastrointestinal Drug TransportAnesthesiology, 2009
- Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infantsThe Journal of Pediatrics, 2000
- Pharmacokinetics of continuous infusions of fentanyl in critically ill childrenCritical Care Medicine, 1993
- PHARMACOKINETICS OF METHADONE IN CHILDREN AND ADOLESCENTS IN THE PERIOPERATIVE PERIODAnesthesiology, 1987
- FENTANYL PHARMACOKINETICS IN THE PEDIATRIC POPULATIONAnesthesiology, 1984
- Pharmacodynamics and Pharmacokinetics of Methadone during the Perioperative PeriodAnesthesiology, 1982